戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              TGEV nsp1 also suppressed protein translation in cell-fr
2                                              TGEV required R1 of fAPN, while FCoV and CCoV required b
3  ORF 3B, E, and M genes [TGEV-Rep(AvrII) and TGEV-Rep(EcoNI), respectively].
4 wed some cross-reactivity to TGEV Miller and TGEV Purdue antisera, while N protein presented some cro
5 herichia coli-expressed recombinant PEDV and TGEV nucleocapsid (N) proteins, and sequence analysis su
6 ween porcine enteric coronaviruses, PEDV and TGEV, in CCIF assays supports the idea that these two sp
7    To prepare a packaging system to assemble TGEV replicon particles (TGEV VRP), the TGEV E gene was
8 ross-reactions were observed by CCIF between TGEV Miller hyperimmune pig antisera and all PEDV strain
9                            Nineteen complete TGEV genomes and a single strain of porcine respiratory
10                  Under identical conditions, TGEV-GFP2 spread throughout ST cell cultures, expressed
11 ding canine coronavirus, porcine coronavirus TGEV, and human coronavirus HCV-229E.
12 e transmissible gastroenteritis coronavirus (TGEV), canine coronavirus (CCoV), and human coronavirus
13 ine CoVs (transmissible gastroenteritis CoV [TGEV] and porcine respiratory CoV [PRCV]) was mediated t
14 virus (TGEV) infectious construct designated TGEV 1000.
15 djoining cDNA subclones that span the entire TGEV genome were isolated.
16 ted Salmonella vaccine constructs expressing TGEV S protein epitopes were studied and evaluated for i
17 ere key determinants of host range for FCoV, TGEV, and CCoV.
18 type FIPV strains tested positive, but FECV, TGEV, and CCV tested negative.
19 ution caused a gain of receptor activity for TGEV but not for FCoV or CCoV.
20 s investigated by testing clinical cases for TGEV by real time RT-PCR between January 2008 and Novemb
21 ntain a host factor(s) that is essential for TGEV nsp1-induced translational suppression.
22    As the E and M proteins are essential for TGEV virion budding, these replicon RNAs should replicat
23 B and E genes or the ORF 3B, E, and M genes [TGEV-Rep(AvrII) and TGEV-Rep(EcoNI), respectively].
24                The development of infectious TGEV replicon particles should assist studies of TGEV re
25 acent cDNA subclones, resulting in an intact TGEV cDNA construct of approximately 28.5 kb in length.
26     Transcripts derived from the full-length TGEV construct were infectious, and progeny virions were
27 e epitopes in the context of the full-length TGEV spike protein.
28  to generate an infectious cDNA construct of TGEV could theoretically be used to precisely reconstruc
29         Full-length infectious constructs of TGEV will permit the precise genetic modification of the
30 n, genetic characteristics, and evolution of TGEV and PRCV circulating in the US.
31 GEV, and resulted in a "variant" genotype of TGEV.
32  of cancer cell proliferation, inhibition of TGEV replication for anticoronavirus activity, and suppr
33                                Prevalence of TGEV ranged between 3.8-6.8% and peaked during cold mont
34  replicon particles should assist studies of TGEV replication and assembly as well as facilitate the
35                   Identification of PEDV- or TGEV-specific antigenic regions allows the development o
36                               Sixteen of our TGEV strains share 8 unique deletions and 119 distinct a
37  system to assemble TGEV replicon particles (TGEV VRP), the TGEV E gene was cloned into a Venezuelan
38 one epitope on the N-terminal region of PEDV/TGEV N protein that contributed to this cross-reactivity
39                              None of the pig TGEV antisera neutralized PEDV and vice versa.
40                                  Recombinant TGEV was not released from these cultures.
41 by hamster kidney (BHK) cells, a recombinant TGEV (TGEV-GFP2) was isolated that replicated efficientl
42          Using this construct, a recombinant TGEV was constructed that replaced open reading frame (O
43 S 197del PC177), and two representative U.S. TGEV strains (Miller and Purdue) were conducted by cell
44    Likewise, PRRSV did not impact a specific TGEV-associated enhancement of IL-8 expression.
45 ster kidney (BHK) cells, a recombinant TGEV (TGEV-GFP2) was isolated that replicated efficiently and
46                                          The TGEV and SARS-CoV N proteins are RNA chaperons with long
47 a and the TGEV C epitope but not against the TGEV A epitope.
48            Moreover, mucosal IgA against the TGEV C epitope was only detected with serovar Typhimuriu
49 emic and mucosal antibody titers against the TGEV epitopes compared to the parental vaccine.
50 emic antibodies against both fimbria and the TGEV C epitope but not against the TGEV A epitope.
51 syndrome coronavirus, a betacoronavirus, the TGEV nsp1 protein was unable to bind 40S ribosomal subun
52 equently infected with VEE VRPs carrying the TGEV E gene.
53 ctor and VEE replicon particles encoding the TGEV E protein were isolated [VEE-TGEV(E)].
54 re compared for their ability to express the TGEV C and A epitopes in the context of the heterologous
55 ially degraded chimeric subunits lacking the TGEV epitopes.
56 , demonstrating the single-hit nature of the TGEV replicon RNAs.
57 mble TGEV replicon particles (TGEV VRP), the TGEV E gene was cloned into a Venezuelan equine encephal
58   The M protein was highly cross-reactive to TGEV and PRCV antisera.
59 WV particles showed some cross-reactivity to TGEV Miller and TGEV Purdue antisera, while N protein pr
60 N protein presented some cross-reactivity to TGEV Miller.
61 ated for improved humoral immune response to TGEV.
62 he biological characteristics of the variant TGEV, and resulted in a "variant" genotype of TGEV.
63 ation event occurred between the ''variant'' TGEV and PRCV.
64 th TGEV-Rep(AvrII) (E gene deletion) and VEE-TGEV(E) RNA transcripts or transfected with TGEV-Rep(Avr
65 coding the TGEV E protein were isolated [VEE-TGEV(E)].
66 V), and transmissible gastroenteritis virus (TGEV) and clinical fluid samples from cats with effusive
67 DV) and transmissible gastroenteritis virus (TGEV) are economically important swine enteropathogenic
68 ing the transmissible gastroenteritis virus (TGEV) C (379-388) and A (521-531) epitopes of the spike
69 sity of transmissible gastroenteritis virus (TGEV) in the United States (US) was investigated by test
70 lated a transmissible gastroenteritis virus (TGEV) infectious construct designated TGEV 1000.
71         Transmissible gastroenteritis virus (TGEV) is a porcine coronavirus that causes diarrhea, lea
72  pDC to transmissible gastroenteritis virus (TGEV) or the Toll-like receptor 9 agonist, oligodeoxynuc
73 tein of transmissible gastroenteritis virus (TGEV), an alphacoronavirus, efficiently suppressed prote
74 ruct of transmissible gastroenteritis virus (TGEV), an important pathogen in swine.
75 against transmissible gastroenteritis virus (TGEV), porcine respiratory coronavirus (PRCV), or porcin
76 porcine transmissible gastroenteritis virus (TGEV), use aminopeptidase N (APN) as their cellular rece
77 can utilize human but not porcine APN, while TGEV can utilize porcine but not human APN.
78     BHK cells were either cotransfected with TGEV-Rep(AvrII) (E gene deletion) and VEE-TGEV(E) RNA tr
79 -TGEV(E) RNA transcripts or transfected with TGEV-Rep(AvrII) RNA transcripts and subsequently infecte